REGN

Regeneron Pharmaceuticals
D

REGN

700.66
USD
4.37
(0.63%)
مغلق
حجم التداول
17,682
الربح لكل سهم
46
العائد الربحي
0.13
P/E
18
حجم السوق
76,599,431,690
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    ABBV
    ABBV
    1.200
    (0.60%)
    202.140 USD
    AMGN
    AMGN
    5.10
    (1.71%)
    303.15 USD
    BMY
    BMY
    0.050
    (0.09%)
    55.840 USD
    GILD
    GILD
    -0.140
    (-0.13%)
    109.920 USD
    JNJ
    JNJ
    2.680
    (1.68%)
    162.370 USD
    LLY
    LLY
    0.67
    (0.08%)
    874.04 USD
    MRNA
    MRNA
    1.785
    (5.29%)
    35.535 USD
    NVS
    NVS
    2.100
    (1.96%)
    109.370 USD
    PFE
    PFE
    0.405
    (1.56%)
    26.305 USD
    المزيد
الأخبار
المقالات

العنوان: Regeneron Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).